Comite F, Cassorla F, Barnes K M, Hench K D, Dwyer A, Skerda M C, Loriaux D L, Cutler G B, Pescovitz O H
JAMA. 1986 May 16;255(19):2613-6.
The long-acting analogue of luteinizing hormone releasing hormone, D-Trp6-Pro9-NEt-LHRH (LHRHa), is effective in the short-term treatment of central precocious puberty. We report the results of two to four years of LHRHa therapy in 27 children with this disorder. Secondary sex characteristics regressed in most patients. Sex steroid levels and basal and LHRH-stimulated gonadotropin levels remained suppressed compared with pretreatment values. Linear growth rates decreased from 11.0 +/- 0.8 (SEM) cm/yr before treatment to 5.7 +/- 0.4 cm/yr at two years of treatment and 3.7 +/- 0.7 cm/yr at four years of treatment. Predicted heights by the Bayley-Pinneau method increased from 156.4 +/- 2.0 cm before treatment to 162.3 +/- 2.3 cm at two years and 163.4 +/- 2.4 cm at three years. Five patients treated for four years had a mean increase in predicted height of 5.5 cm. To date no adverse effects have been observed. However, the ultimate safety of this analogue is not known. We conclude that LHRHa appears to be an effective long-term therapy for central precocious puberty.
促黄体生成激素释放激素的长效类似物D-Trp6-Pro9-NEt-LHRH（LHRHa）在中枢性性早熟的短期治疗中有效。我们报告了27例患有这种疾病的儿童接受LHRHa治疗两到四年的结果。大多数患者的第二性征消退。与治疗前值相比，性类固醇水平以及基础和LHRH刺激的促性腺激素水平仍受到抑制。线性生长速率从治疗前的11.0±0.8（SEM）厘米/年降至治疗两年时的5.7±0.4厘米/年和治疗四年时的3.7±0.7厘米/年。根据贝利 - 平诺方法预测的身高从治疗前的156.4±2.0厘米增加到两年时的162.3±2.3厘米和三年时的163.4±2.4厘米。接受四年治疗的5名患者预测身高平均增加5.5厘米。迄今为止，未观察到不良反应。然而，这种类似物的最终安全性尚不清楚。我们得出结论，LHRHa似乎是中枢性性早熟的一种有效的长期治疗方法。
